Cerebrovascular disease treatment device

Abstract

Provided is a treatment device for cerebrovascular disorders that is capable of, while efficiently supplying oxygen to the brain, surely controlling the oxygen concentration in the brain tissue so as to avoid an excessive increase therein. This treatment device for cerebrovascular disorders comprises a body unit 10 provided with an injection unit 30 that is inserted into a living body and injects a fluid, oxygen concentration measurement units 23 that are disposed at at least two positions in the living body, and a flow rate adjustment unit 45 that adjusts the flow rate of the fluid injected by the injection unit 30, wherein the flow rate adjustment unit 45 adjusts the flow rate of the fluid injected by the injection unit 30 depending on the oxygen concentrations at the at least two positions in the living body measured by the oxygen concentration measurement units 23.

Description

[Technical Field]

[0001] The present invention relates to a device for treating cerebrovascular disorders that is inserted from the spine and delivers a highly oxygenated solution (including a hyperoxic solution) to the brain. [Background technology]

[0002] Established treatment methods for cerebral infarction include thrombolytic therapy and thrombectomy. However, these treatments are often difficult to implement due to the risk of bleeding and poor access. For this reason, most treatments for cerebral infarction are limited to medical treatment.

[0003] One possible treatment for cerebral infarction is to approach the brain with a highly oxygenated solution and deliver oxygen via a route other than the blood vessels. For example, Patent Document 1 discloses a therapeutic device for injecting highly oxygenated cerebrospinal fluid to treat cerebral infarction. [Prior art documents] [Patent documents]

[0004] [Patent Document 1] U.S. Patent No. 4,686,085 Summary of the Invention [Problem to be solved by the invention]

[0005] Continuing to circulate a highly oxygenated solution through the brain at a high flow rate carries the risk of causing hyperoxia damage, increased intracranial pressure, etc. Patent Document 1 describes controlling the flow rate and oxygen concentration of the solution based on the oxygen concentration of cerebrospinal fluid in the cisterna magna, but does not disclose a specific control method. Furthermore, although the oxygen concentration in the cisterna magna is measured, it is unclear whether hyperoxia damage, etc. can be sufficiently prevented.

[0006] The present invention has been made to solve the above-mentioned problems, and aims to provide a cerebrovascular disorder treatment device that can efficiently supply oxygen to the brain while reliably controlling the oxygen concentration in brain tissue so that it does not become too high. [Means for solving the problem]

[0007] The cerebrovascular disorder treatment device according to the present invention, which achieves the above-mentioned object, comprises a main body section having an injector section that is inserted into the spinal canal from the lumbar vertebrae to inject a fluid containing artificial cerebrospinal fluid and an outlet section that discharges cerebrospinal fluid, oxygen concentration measuring sections that are arranged at at least two locations in a living body, and a flow rate adjusting section that adjusts the flow rate of the fluid containing artificial cerebrospinal fluid injected by the injector section or the flow rate of the cerebrospinal fluid discharged by the outlet section, wherein the flow rate adjusting section reduces the flow rate of the fluid containing artificial cerebrospinal fluid injected by the injector section when the oxygen concentration in the living body measured by one of the oxygen concentration measuring sections exceeds a predetermined upper limit value, and further reduces the flow rate of the fluid containing artificial cerebrospinal fluid injected by the injector section when the oxygen concentration in the living body measured by the other oxygen concentration measuring section exceeds a predetermined upper limit value. artificial of fluids, including cerebrospinal fluid Stop the injection to make and when the oxygen concentration in the living body measured by one or the other of the oxygen concentration measuring units falls below a predetermined lower limit, the injector resumes injecting the fluid containing the artificial cerebrospinal fluid. As a result, all of the oxygen concentrations in the living body measured by the oxygen concentration measuring unit are equal to or lower than the upper limit value. The aforementioned The amount of the liquid to be injected by the injection unit is between the lower limit and the upper limit. artificial The flow rate of a fluid containing cerebrospinal fluid or the flow rate of the cerebrospinal fluid discharged by the discharge portion is adjusted.

[0009] The cerebrovascular disorder treatment device according to the present invention, which achieves the above-mentioned object, comprises a main body portion having an injection portion that is inserted into the spinal canal from the lumbar vertebrae to inject a fluid containing artificial cerebrospinal fluid and an outlet portion that discharges the cerebrospinal fluid, a pressure measurement portion disposed in a flow path of the main body portion, and a flow rate adjustment portion that adjusts the flow rate of the fluid containing artificial cerebrospinal fluid injected by the injection portion or the flow rate of the cerebrospinal fluid discharged by the outlet portion, and the flow rate adjustment portion adjusts the flow rate of the fluid containing artificial cerebrospinal fluid injected by the injection portion when the pressure inside the living body measured by the pressure measurement portion exceeds a predetermined upper limit value. Stop the injection Let and when the pressure inside the living body measured by the pressure measuring unit falls below a predetermined lower limit, the injection unit resumes the injection of the fluid containing the artificial cerebrospinal fluid.The pressure inside the living body measured by the pressure measuring unit is equal to or lower than the upper limit value. The aforementioned The amount of the liquid to be injected by the injection unit is between the lower limit and the upper limit. artificial The flow rate of a fluid containing cerebrospinal fluid or the flow rate of the cerebrospinal fluid discharged by the discharge unit is adjusted, the cerebrospinal fluid discharged by the discharge unit is collected, and the collected fluid can be further injected into a living body together with the fluid containing the artificial cerebrospinal fluid injected by the injection unit. [Effects of the Invention]

[0011] The cerebrovascular disorder treatment device configured as described above adjusts the flow rate or oxygen concentration of the fluid injected by the injection section based on the oxygen concentrations at at least two locations in the body, thereby efficiently supplying oxygen to the brain while reliably controlling the oxygen concentration in brain tissue to prevent it from becoming too high.

[0012] The flow rate adjusting unit may be configured to reduce or stop the flow rate of the fluid injected by the injecting unit when any of the oxygen concentrations measured by the oxygen concentration measuring unit at at least two locations in the living body exceeds a predetermined upper limit. This allows the fluid to have a sufficient oxygen concentration while preventing any of the oxygen concentrations measured at multiple locations from exceeding the upper limit, thereby enabling oxygen to be efficiently supplied to the brain.

[0013] The flow rate adjusting unit may adjust the flow rate of the fluid injected by the injector so that the oxygen concentrations measured by the oxygen concentration measuring unit at at least two locations in the living body are between the predetermined upper and lower limits after reducing or stopping the flow rate of the fluid injected by the injector. This controls the oxygen concentrations at multiple locations in the living body within a certain range, thereby reliably preventing the oxygen concentration in brain tissue from becoming too high.

[0014] The oxygen concentration adjusting unit may be configured to reduce the oxygen concentration of the fluid injected by the injecting unit when either of the oxygen concentrations measured by the oxygen concentration measuring unit at at least two locations in the living body exceeds a predetermined upper limit value. This allows the fluid to have a sufficient oxygen concentration while preventing any of the oxygen concentrations measured at multiple locations from exceeding the upper limit value, thereby enabling oxygen to be efficiently supplied to the brain.

[0015] The oxygen concentration adjusting unit may adjust the oxygen concentration of the fluid injected by the injecting unit so that the oxygen concentrations measured by the oxygen concentration measuring unit at at least two locations in the living body are between the predetermined upper and lower limits after reducing the oxygen concentration of the fluid injected by the injecting unit. This controls the oxygen concentrations at multiple locations in the living body within a certain range, thereby reliably preventing the oxygen concentration of the fluid from becoming too high.

[0016] Furthermore, the cerebrovascular disorder treatment device configured as described above can efficiently supply oxygen to the brain while reliably controlling it without the risk of increasing intracranial pressure by adjusting the flow rate of the fluid injected by the injection section or the flow rate of the fluid discharged by the discharge section according to the pressure inside the body measured by the pressure measurement section. [Brief explanation of the drawings]

[0017] [Figure 1] 1 is a configuration diagram of a cerebrovascular disorder treatment device according to an embodiment of the present invention. [Figure 2] FIG. [Figure 3] 10 is a flowchart of a treatment using the cerebrovascular disorder treatment device when adjusting the flow rate of a fluid. [Figure 4] 10 is a graph showing a first pattern of changes in oxygen concentration over time in treatment using a cerebrovascular disorder treatment device. [Figure 5] 10 is a graph showing a second pattern of changes in oxygen concentration over time in treatment using a cerebrovascular disorder treatment device. [Figure 6]10 is a flowchart of a treatment using the cerebrovascular disorder treatment device when adjusting the oxygen concentration of a fluid. DETAILED DESCRIPTION OF THE INVENTION

[0018] Hereinafter, an embodiment of the present invention will be described with reference to the drawings. Note that the dimensional proportions in the drawings may be exaggerated for the sake of explanation and may differ from the actual proportions. In this specification, the side of the main body 10 that is inserted into a living body will be referred to as the "distal end" or "distal side," and the side that is operated by the hand will be referred to as the "proximal end" or "proximal side." Note that the technical scope of the present invention is not limited to the embodiment of the present invention described below.

[0019] The cerebrovascular disorder treatment device according to an embodiment of the present invention treats cerebral infarction by delivering the main body 10 to the vicinity of the brain, injecting highly oxygenated artificial cerebrospinal fluid (including artificial spinal fluid), and aspirating the cerebrospinal fluid at the base end.

[0020] As shown in FIG. 1, the cerebrovascular disorder treatment device has a main body 10 that is inserted into a living body, and a control device 12 that adjusts the flow rate and oxygen concentration of a fluid supplied to the main body 10. The main body 10 is inserted into the spinal canal from the lumbar vertebrae of the human body, and its tip is delivered to the position of the cisterna magna. An injection section 30 for introducing a fluid is provided at the tip of the main body 10. The main body 10 also has oxygen concentration measuring sections 23 at two locations within the living body. When the main body 10 is inserted into the living body, the oxygen concentration measuring sections 23 are located near the cisterna magna and near the lumbar vertebrae, respectively.

[0021] The control device 12 has a fluid supply unit 40 that adds oxygen to the fluid and supplies it, a pump unit 41 that causes the fluid from the fluid supply unit 40 to flow into the main body unit 10, and a discharge drive unit 42 that discharges the fluid from the main body unit 10. An oxygen concentration adjustment unit 46 is connected to the fluid supply unit 40 and adjusts the concentration of oxygen added by the fluid supply unit 40. The control device 12 also has a flow rate adjustment unit 45 that is connected to the two oxygen concentration measurement units 23, receives information on the oxygen concentration of the fluid, controls the pump unit 41 based on that information, and adjusts the flow rate of the fluid supplied to the main body unit 10. The oxygen concentration measurement units 23 and the flow rate adjustment unit 45 are connected by a connection line that is provided along the length of the main body unit 10.

[0022] As shown in FIG. 2, the main body 10 has a long tube main body 20. The tube main body 20 has a pressure measurement unit 22 at its tip. As described above, the tube main body 20 is provided with oxygen concentration measurement units 23 at two locations. An injection unit 30 that opens toward the tip is formed at the tip of the tube main body 20. An outlet unit 31 is formed in the middle of the tube main body 20. If the oxygen concentration measurement unit 23 is positioned so that it protrudes outside the main body 10, there is a risk that the oxygen concentration measurement unit 23 will get caught on the insertion port when the main body is inserted into the lumbar vertebrae. Therefore, a recess may be formed in the main body 10, and the oxygen concentration measurement unit may be positioned in the recess.

[0023] The base end of the tube main body 20 branches into two, an inlet tube 35 and an outlet tube 36. An inlet section 35a is provided at the base end of the inlet tube 35. A pump section 41 of the control device 12 is connected to the inlet section 35a. An outlet section 36a is provided at the base end of the outlet tube 36. A discharge drive section 42 of the control device 12 is connected to the outlet section 36a. Hubs, for example, can be used as the inlet section 35a or the outlet section 36a. The inlet section 35a and the injection section 30, and the outlet section 36a and the discharge section 31 are each connected by a lumen that runs along the length of the tube main body 20.

[0024] The tube body 20 is preferably made of a material having a certain degree of flexibility, such as polyolefins such as polyethylene, polypropylene, polybutene, ethylene-propylene copolymer, ethylene-vinyl acetate copolymer, ionomer, or a mixture of two or more of these, soft polyvinyl chloride resin, polyamide, polyamide elastomer, polyester, polyester elastomer, polyurethane, fluororesin such as polytetrafluoroethylene, silicone rubber, latex rubber, etc.

[0025] Next, a treatment method using the main body 10 of this embodiment will be described. When a patient suffers from cerebral infarction, the main body 10 is percutaneously inserted into the living body and introduced into the spinal canal through the space between the lumbar vertebrae or the space between the lumbar vertebrae and the sacrum. Specifically, the main body 10 is introduced into the spinal canal using the L3-L4, L4-L5, or L5-S1 space. However, the main body 10 may also be introduced into the spinal canal from a position other than these.

[0026] The main body 10 introduced into the spinal canal is inserted toward the brain. The main body 10 is inserted until the injection section 30 at the tip reaches the vicinity of the brain. The maximum insertion position of the main body 10 is preferably the cisterna magna.

[0027] Next, the flow of fluid flow rate adjustment will be described. In this example, the oxygen concentration adjustment unit 46 constantly maintains the oxygen concentration of the fluid supplied from the fluid supply unit 40. After the main body unit 10 is inserted, as shown in FIG. 3, the flow rate adjustment unit 45 detects the oxygen concentrations measured by the oxygen concentration measurement units 23 at two locations (S1). Then, the flow rate adjustment unit 45 starts driving the pump unit 41 to start circulating the fluid (S2). The fluid supplied from the pump unit 41 to the main body unit 10 is injected into the cerebrospinal fluid from the injection unit 30. When the fluid is supplied, the discharge drive unit 42 is also operated, and the fluid (cerebrospinal fluid) in the spinal canal is aspirated from the discharge unit 31. It is preferable that the amount of fluid aspirated is equal to the amount of fluid injected from the injection unit 30. This can suppress an increase in intracranial pressure.

[0028] As shown in Figure 4, from time T0 when fluid supply begins, the oxygen concentration near the cisterna magna (shown by the solid line) and the oxygen concentration near the lumbar vertebrae (shown by the dashed-dotted line) gradually increase. The flow rate adjuster 45 continues to monitor the oxygen concentrations measured by the oxygen concentration measuring units 23 from step S2 onward during this flow. If the oxygen concentration measured by any of the oxygen concentration measuring units 23 reaches a critical value, the flow rate adjuster 45 immediately stops supplying the fluid or reduces the flow rate of the fluid being supplied. Furthermore, if the oxygen concentration near the cisterna magna does not increase after fluid supply begins, or if only the oxygen concentration near the cisterna magna increases but not the oxygen concentration near the lumbar vertebrae, the flow rate adjuster 45 determines that there is a circulation abnormality and stops supplying the fluid.

[0029] As shown in FIG. 4, an upper limit value obtained by adding a certain value to the required oxygen concentration and a lower limit value obtained by subtracting a certain value from the required oxygen concentration are preset. The flow rate adjustment unit 45 controls the oxygen concentration so that both the oxygen concentration near the large cisterna and the oxygen concentration near the lower back pain area are between the upper and lower limits. Because the fluid supplying oxygen is injected from the injection unit 30 near the large cisterna, the oxygen concentration near the large cisterna increases first. After starting fluid circulation in S2, the flow rate adjustment unit 45 determines whether the oxygen concentration near the large cisterna has reached the upper limit value (S3). If the oxygen concentration near the large cisterna reaches the upper limit value at time T1, the flow rate adjustment unit 45 reduces the flow rate of the fluid, thereby reducing the circulation amount (S4). This controls the oxygen concentration near the large cisterna to be constant near the upper limit value. The flow rate of the fluid is controlled so that the oxygen concentration is maintained within approximately ±10% of the upper limit value. When the amount of fluid circulation decreases, the oxygen concentration near the lumbar vertebrae increases toward the upper limit while slowing down the rate of increase.

[0030] The flow rate adjusting unit 45 determines whether the oxygen concentration near the lumbar vertebrae has reached an upper limit (S5). If the oxygen concentration near the lumbar vertebrae has reached the upper limit at time T2, the flow rate adjusting unit 45 stops the circulation of the fluid (S6). This causes both the oxygen concentration near the cisterna magna and the oxygen concentration near the lumbar vertebrae to decrease.

[0031] After the circulation of the fluid is stopped, the flow rate adjuster 45 determines whether either the oxygen concentration near the large cisterna or the oxygen concentration near the lumbar vertebrae has dropped to a preset lower limit (S7). In FIG. 4, the oxygen concentration near the large cisterna has dropped to the lower limit first at time T3. In this case, the flow rate adjuster 45 resumes the circulation of the fluid at time T3 (S8). In FIG. 5, the oxygen concentration near the lumbar vertebrae has dropped to the lower limit first at time T3. In this case, the flow rate adjuster 45 resumes the circulation of the fluid at time T3 (S8). As a result, both oxygen concentrations begin to rise again.

[0032] After that, the process returns to S3 and the same control is repeated. As a result, the oxygen concentration near the cisterna magna and the oxygen concentration near the lumbar vertebrae are both controlled to be between the upper and lower limits. This effectively supplies oxygen to the brain while preventing the oxygen concentration from becoming too high, reducing the risk of hyperoxia and other disorders.

[0033] During circulation of the fluid, the intracranial pressure measured by the pressure measuring unit 22 is checked at any time. If the intracranial pressure exceeds a certain value, the circulation of the fluid is stopped.

[0034] The fluid collected by the discharge drive unit 42 is discarded as is, but the collected fluid may be passed through a filter and then supplied to the brain together with the fluid from the fluid supply unit 40.

[0035] The circulation of the fluid can be carried out for a certain period of time, for example. After the certain period of time has elapsed, the circulation of the fluid is stopped, and the main body 10 is removed from the living body, thereby completing the treatment.

[0036] In this example, the circulation of the fluid is stopped at S7, but the flow rate of the fluid may be further reduced than when the circulation of the fluid was reduced at S4, and the oxygen concentration of the circulating fluid may be controlled to decrease while maintaining the circulation of the fluid.

[0037] In addition, in this example, the oxygen concentration of the fluid is constant, and the flow rate of the fluid is adjusted to control the oxygen concentration in the living body to be within a certain range, but the flow rate of the fluid may be kept constant, and the oxygen concentration of the fluid may be adjusted to control the oxygen concentration in the living body to be within a certain range.

[0038] As shown in FIG. 6, steps S2-1 to S2-3 are the same as steps S1 to S3 in FIG. 3. In step S2-4, the oxygen concentration adjuster 46 reduces the oxygen concentration of the fluid supplied from the fluid supply unit 40. As a result, as shown at time T1 to time T2 in FIG. 4, the oxygen concentration near the large cisterna is maintained constant near the upper limit, while the oxygen concentration near the lumbar vertebrae is increased. When the oxygen concentration near the lumbar vertebrae reaches the upper limit (S2-5), the oxygen concentration adjuster 46 stops the supply of oxygen to the fluid (S2-6). Thereafter, when either the oxygen concentration near the large cisterna or the oxygen concentration near the lumbar vertebrae drops to the lower limit (S2-7), the oxygen concentration adjuster 46 resumes the supply of oxygen to the fluid (S2-8). In this way, by adjusting the oxygen concentration to be added to the fluid, the oxygen concentrations near the large cisterna and the oxygen concentration near the lumbar vertebrae can both be controlled to be between the upper and lower limits, just as in the case of adjusting the flow rate.

[0039] As described above, the cerebrovascular disorder treatment device according to this embodiment includes main body 10 having injection section 30 that is inserted into a living body and injects a fluid, oxygen concentration measurement sections 23 that are provided at at least two locations in the living body, and flow rate adjustment section 45 that adjusts the flow rate of the fluid injected by injection section 30, where flow rate adjustment section 45 adjusts the flow rate of the fluid injected by injection section 30 in accordance with the oxygen concentrations at the at least two locations in the living body measured by oxygen concentration measurement section 23. Alternatively, the cerebrovascular disorder treatment device according to this embodiment includes main body 10 having injection section 30 that is inserted into a living body and injects a fluid, oxygen concentration measurement sections 23 that are provided at at least two locations in the living body, and oxygen concentration adjustment section 46 that adjusts the oxygen concentration of the fluid injected by injection section 30, where oxygen concentration adjustment section 46 adjusts the oxygen concentration of the fluid injected by injection section 30 in accordance with the oxygen concentrations at the at least two locations in the living body measured by oxygen concentration measurement section 23. The cerebrovascular disorder treatment device configured in this manner adjusts the flow rate or oxygen concentration of the fluid to be infused by the infusion unit 30 based on the oxygen concentrations at at least two locations in the living body. This allows for efficient supply of oxygen to the brain while reliably controlling the oxygen concentration of the infused fluid to prevent it from becoming too high. The reason why the oxygen concentration measurement unit 23 is installed in two locations, near the cisterna magna and near the lumbar vertebrae, is explained below. From the perspective of preventing hyperoxic injury, it is desirable to install the oxygen concentration measurement unit 23 in the brain. However, due to the structure of the human body, it is difficult to install the oxygen concentration measurement unit 23 in the brain. Therefore, in this embodiment, by measuring the oxygen concentration near the cisterna magna, where the fluid is injected, and also near the lumbar vertebrae, which are distant from the injection site, it is possible to estimate oxygen consumption and oxygen diffusion in the living body.

[0040] Furthermore, flow rate adjustment unit 45 may be configured to reduce or stop the flow rate of the fluid injected by injection unit 30 when either of the oxygen concentrations measured by oxygen concentration measurement unit 23 at at least two locations in the living body exceeds a predetermined upper limit. This makes it possible to provide the fluid with a sufficient oxygen concentration while preventing any of the oxygen concentrations measured at multiple locations from exceeding the upper limit, thereby enabling oxygen to be efficiently supplied to the brain.

[0041] Furthermore, after reducing or stopping the flow rate of the fluid injected by injector 30, flow rate adjuster 45 may adjust the flow rate of the fluid injected by injector 30 so that the oxygen concentrations at at least two locations in the living body measured by oxygen concentration measuring unit 23 are between predetermined upper and lower limit values. This controls the oxygen concentrations at multiple locations in the living body within a certain range, thereby reliably preventing the oxygen concentration in brain tissue from becoming too high.

[0042] Furthermore, oxygen concentration adjusting unit 46 may be configured to reduce the oxygen concentration of the fluid injected by injecting unit 30 when either of the oxygen concentrations measured by oxygen concentration measuring unit 23 at at least two locations in the living body exceeds a predetermined upper limit. This makes it possible to provide the fluid with a sufficient oxygen concentration while preventing any of the oxygen concentrations measured at multiple locations from exceeding the upper limit, thereby enabling oxygen to be efficiently supplied to the brain.

[0043] Furthermore, oxygen concentration adjusting unit 46 may adjust the oxygen concentration of the fluid injected by injecting unit 30 so that, after reducing the oxygen concentration of the fluid injected by injecting unit 30, the oxygen concentrations measured by oxygen concentration measuring unit 23 at at least two locations in the living body are between predetermined upper and lower limit values. This controls the oxygen concentrations at multiple locations in the living body within a certain range, thereby reliably preventing the oxygen concentration in brain tissue from becoming too high.

[0044] The cerebrovascular disorder treatment device according to this embodiment includes a main body 10 that is inserted into a living body and has an infusion unit 30 for injecting a fluid and a discharge unit 31 for discharging the fluid, a pressure measurement unit 22 disposed in a flow path of the main body 10, and a flow rate adjustment unit 45 that adjusts the flow rate of the fluid injected by the infusion unit 30 or the flow rate of the fluid discharged by the discharge unit 31, and the flow rate adjustment unit 45 adjusts the flow rate of the fluid injected by the infusion unit 30 or the flow rate of the fluid discharged by the discharge unit 31 in accordance with the pressure inside the living body measured by the pressure measurement unit 22. The cerebrovascular disorder treatment device configured in this manner adjusts the flow rate of the fluid injected by the infusion unit 30 or the flow rate of the fluid discharged by the discharge unit 31 in accordance with the pressure inside the living body measured by the pressure measurement unit 22, thereby enabling efficient supply of oxygen to the brain while controlling it without the risk of increasing intracranial pressure.

[0045] In addition, the cerebrovascular disorder treatment device of this embodiment comprises a main body 10 having an injection section 30 that is inserted into a living body and injects a fluid, an oxygen concentration measuring section 23 that is placed inside the living body, and a flow rate adjusting section 45 that adjusts the flow rate of the fluid injected by the injection section 30, and the flow rate adjusting section 45 reduces or stops the flow rate of the fluid injected by the injection section 30 when the oxygen concentration inside the living body measured by the oxygen concentration measuring section 23 exceeds a predetermined upper limit value.

[0046] The present invention is not limited to the above-described embodiment, and various modifications can be made by those skilled in the art within the technical concept of the present invention.

[0047] In the above-described embodiment, the oxygen concentration measuring units 23 are placed at two locations, near the cisterna magna and near the lumbar vertebrae, but the oxygen concentration measuring units 23 may be placed at three or more locations in the living body. In this case, the flow rate or oxygen concentration of the fluid is adjusted so that the oxygen concentrations measured by all of the oxygen concentration measuring units 23 are between an upper limit and a lower limit. Furthermore, the locations at which the oxygen concentration measuring units 23 are placed are not limited to the above-described locations, and the oxygen concentration measuring units 23 may be placed at any location as needed.

[0048] In the above-described embodiment, the main body 10 has a double lumen structure having a lumen communicating with the inlet 30 and a lumen communicating with the outlet 31, but it may also have a single lumen or a multi-lumen structure.

[0049] In the above-described embodiment, the flow rate adjusting unit 45 adjusts the flow rate of the fluid based on the oxygen concentration measured by the oxygen concentration measuring unit 23. However, the flow rates of the infused and discharged fluids may also be adjusted based on the intracranial pressure measured by the pressure measuring unit 22 so that the intracranial pressure is within a certain range. Because pressure is constant within the subarachnoid space, control can be performed based on a pressure value measured at a single location. The flow rate adjusting unit 45 adjusts the amount of circulating fluid so that the pressure value measured by the pressure measuring unit 22 is between a preset upper limit and a preset lower limit. Note that the position of the pressure measuring unit 22 is not limited to a position within the body of the main unit 10, but may be located anywhere within the flow path through which the fluid circulates.

[0050] The fluid supply unit 40 may adjust the temperature by cooling or heating the fluid to be supplied. The fluid supply unit 40 may also have a filter that allows the fluid to pass through, or a valve such as an air trap.

[0051] In the above-described embodiment, the main body 10 is inserted from the lumbar vertebrae, but it may be inserted from any other position that allows access to the subarachnoid space, such as the thoracic vertebrae, cisterna magna, or lateral ventricle.

[0052] In the above-described embodiment, the position of the injection part 30 in the living body is near the cisterna magna, but it may be at any other position, such as the thoracic vertebrae or the lateral ventricle, as long as it is accessible to the subarachnoid space.

[0053] The gas added to the fluid may be other gases other than oxygen that are known to have a therapeutic effect on cerebral infarction, such as nitric oxide, hydrogen, helium, or a mixture of these gases.

[0054] The fluid injected from the injection unit 30 may be other than artificial cerebrospinal fluid. The fluid to be highly oxygenated may be a liquid with high gas solubility, such as a fluorocarbon, or an emulsion thereof, or a solution that is harmless to the living body, such as physiological saline. The solution does not have to be highly oxygenated, and may be cooled or heated.

[0055] The cerebrovascular disorder treatment device can also be used for the treatment of diseases other than cerebral infarction. For example, injecting a highly oxygenated solution or forcibly circulating cerebrospinal fluid is thought to be effective for brain diseases such as cerebral hemorrhage, subarachnoid hemorrhage, hydrocephalus, and Alzheimer's disease, as well as spinal cord ischemia, and the cerebrovascular disorder treatment device of this embodiment can be used for these diseases.

[0056] This application is based on Japanese Patent Application No. 2021-30221, filed on February 26, 2021, the disclosures of which are incorporated by reference in their entirety. [Explanation of symbols]

[0057] 10 Main body 12 Control device 20 Tube body 22 Pressure measurement section 23 Oxygen concentration measurement unit 30 Injection part 31 Discharge section 35 Inlet pipe 36 Outlet pipe 40 Fluid supply section 41 Pump section 42 Discharge drive unit 45 Flow rate adjustment section 46 Oxygen concentration adjustment unit

Claims

1. a main body portion that is inserted into the spinal canal from the lumbar vertebrae and has an injecting portion for injecting a fluid including artificial cerebrospinal fluid and an ejecting portion for ejecting the cerebrospinal fluid; an oxygen concentration measuring unit disposed at at least two locations in the living body; a flow rate adjusting unit that adjusts the flow rate of the fluid containing the artificial cerebrospinal fluid injected by the injecting unit or the flow rate of the cerebrospinal fluid discharged by the discharging unit, The flow rate adjustment unit reduces the flow rate of the fluid containing the artificial cerebrospinal fluid that is injected by the injection unit when the oxygen concentration in the living body measured by one of the oxygen concentration measurement units exceeds a predetermined upper limit value, and stops the injection of the fluid containing the artificial cerebrospinal fluid that is injected by the injection unit when the oxygen concentration in the living body measured by the other oxygen concentration measurement unit exceeds a predetermined upper limit value, and resumes the injection of the fluid containing the artificial cerebrospinal fluid that is injected by the injection unit when the oxygen concentration in the living body measured by one or the other oxygen concentration measurement unit falls below a predetermined lower limit value, thereby adjusting the flow rate of the fluid containing the artificial cerebrospinal fluid that is injected by the injection unit or the flow rate of the cerebrospinal fluid that is discharged by the discharge unit so that the oxygen concentrations in the living body measured by the oxygen concentration measurement units are both between the upper limit value and the lower limit value.

2. a main body portion that is inserted into the spinal canal from the lumbar vertebrae and has an injecting portion for injecting a fluid including artificial cerebrospinal fluid and an ejecting portion for ejecting the cerebrospinal fluid; a pressure measuring unit disposed in the flow path of the main body; a flow rate adjusting unit that adjusts the flow rate of the fluid containing the artificial cerebrospinal fluid injected by the injecting unit or the flow rate of the cerebrospinal fluid discharged by the discharging unit, the flow rate adjusting unit stops the injection of the fluid containing the artificial cerebrospinal fluid injected by the injecting unit when the pressure inside the living body measured by the pressure measuring unit exceeds a predetermined upper limit value, and resumes the injection of the fluid containing the artificial cerebrospinal fluid injected by the injecting unit when the pressure inside the living body measured by the pressure measuring unit falls below a predetermined lower limit value, thereby adjusting the flow rate of the fluid containing the artificial cerebrospinal fluid injected by the injecting unit or the flow rate of the cerebrospinal fluid discharged by the discharge unit so that the pressure inside the living body measured by the pressure measuring unit is between the upper limit value and the lower limit value; A cerebrovascular disorder treatment device configured to recover the cerebrospinal fluid discharged by the discharge unit and to inject it into a living body together with a fluid containing the artificial cerebrospinal fluid injected by the injection unit.

3. The device for treating cerebrovascular disorders according to claim 1 or 2, further comprising an oxygen concentration adjusting unit that adjusts the oxygen concentration of the fluid containing the artificial cerebrospinal fluid injected by the injection unit.

4. 3. The device for treating cerebrovascular disorders according to claim 2, wherein the pressure measuring unit is arranged at any position within the flow path through which a fluid circulates, not limited to within a living body.

Images